Orthotopic PRL3+ MHCC-LM3 liver tumors were freshly harvested and dissected into live, single-cell suspensions to compare the percentages of surface PRL3 expression on these ex vivo tumor cells vs. parental MHCC-LM3 cultured cells using PRL3-zumab or cetuximab, a well-known chimeric antibody against the epidermal growth factor receptor (EGFR) as a positive surface protein control (Fig. 2a). The gene discussed is EGFR; the disease is neoplasm.